These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21434476)

  • 41. Immunomodulatory effects of rexinoids.
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
    Mahnke K; Schönfeld K; Fondel S; Ring S; Karakhanova S; Wiedemeyer K; Bedke T; Johnson TS; Storn V; Schallenberg S; Enk AH
    Int J Cancer; 2007 Jun; 120(12):2723-33. PubMed ID: 17315189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
    Barrett LV; Murphy JR; Strom TB; Kirkman RL
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
    [No Abstract]   [Full Text] [Related]  

  • 44. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
    Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
    Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.
    Trendowski M
    Drugs; 2015 Nov; 75(17):1993-2016. PubMed ID: 26501980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current development of new drugs in malignant lymphoma].
    Ogura M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
    [No Abstract]   [Full Text] [Related]  

  • 47. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma.
    Duvic M; Cather J; Maize J; Frankel AE
    Am J Hematol; 1998 May; 58(1):87-90. PubMed ID: 9590158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
    Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
    Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
    Dutcher JP; Wiernik PH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel therapies for chronic lymphocytic leukemia.
    Mavromatis BH; Cheson BD
    Blood Rev; 2004 Jun; 18(2):137-48. PubMed ID: 15010151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diphtheria toxin-based targeted toxin therapy for brain tumors.
    Li YM; Vallera DA; Hall WA
    J Neurooncol; 2013 Sep; 114(2):155-64. PubMed ID: 23695514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 44th annual meeting of the American Society of Hematology. December 7-10, 2002: Philadelphia, Pennsylvania. Short-course chemotherapy without radiation therapy could be sufficient for elderly patients with localized aggressive non-Hodgkin's lymphoma.
    D'Orazio A; Johnson L
    Clin Lymphoma; 2003 Mar; 3(4):203-8. PubMed ID: 12672268
    [No Abstract]   [Full Text] [Related]  

  • 54. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of systemic mastocytosis with denileukin diftitox.
    Quintás-Cardama A; Kantarjian H; Verstovsek S
    Am J Hematol; 2007 Dec; 82(12):1124. PubMed ID: 17665501
    [No Abstract]   [Full Text] [Related]  

  • 57. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
    Frankel AE; Fleming DR; Powell BL; Gartenhaus R
    Expert Opin Biol Ther; 2003 Feb; 3(1):179-86. PubMed ID: 12718740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Dang NH; Fayad L; McLaughlin P; Romaguara JE; Hagemeister F; Goy A; Neelapu S; Samaniego F; Walker PL; Wang M; Rodriguez MA; Tong AT; Pro B
    Br J Haematol; 2007 Aug; 138(4):502-5. PubMed ID: 17608763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
    Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
    Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
    [No Abstract]   [Full Text] [Related]  

  • 60. Denileukin diftitox: a novel immunotoxin.
    Manoukian G; Hagemeister F
    Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.